Autoimmune Hemolytic Anemia Medical Services in China

Autoimmune Hemolytic Anemia (AIHA) is a rare, heterogeneous hematologic disorder characterized by the immune-mediated destruction of autologous red blood cells (RBCs), leading to hemolysis and consequent anemia. It arises when the body’s immune system mistakenly produces autoantibodies—most commonly IgG (warm AIHA) or IgM (cold agglutinin disease)—that bind to RBC surface antigens, triggering complement activation and/or macrophage-mediated phagocytosis in the spleen or liver. Less common subtypes include mixed-type and drug-induced AIHA. Pathogenesis involves loss of B-cell tolerance, dysregulated T-follicular helper cell activity, impaired regulatory T-cell function, and genetic predispositions (e.g., polymorphisms in FCGR genes or HLA-DRB1*03/04). Secondary AIHA may accompany lymphoproliferative disorders (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma), systemic autoimmune diseases (e.g., SLE, rheumatoid arthritis), infections (e.g., Mycoplasma pneumoniae, EBV, HIV), or immunomodulatory therapies. Epidemiologically, AIHA affects approximately 1–3 per 100,000 individuals annually, with bimodal peaks in childhood (often post-infectious) and older adulthood (median age 50–70 years). Females are affected slightly more often than males (F:M ≈ 1.3:1). Risk factors include underlying autoimmune or hematologic malignancies, prior splenectomy, certain medications (e.g., fludarabine, alpha-methyldopa), and genetic susceptibility. Untreated or refractory AIHA can cause profound fatigue, dyspnea, pallor, jaundice, dark urine, tachycardia, and—in severe cases—high-output heart failure, renal injury from hemoglobinuria, or thromboembolic complications due to chronic inflammation and hypercoagulability. Quality of life is significantly impaired: patients report persistent fatigue, reduced physical stamina, anxiety about hemolytic crises, treatment-related side effects (e.g., steroid-induced insomnia, weight gain, osteoporosis), and social withdrawal due to unpredictable symptom flares. Long-term management requires vigilant monitoring for relapse, secondary malignancy, and iatrogenic complications—especially in elderly patients on prolonged immunosuppression. Psychosocial support, patient education on infection prevention, and individualized treatment escalation strategies are integral to holistic care.

Autoimmune hemolytic anemia (AIHA) is a heterogeneous disorder characterized by the production of autoantibodies that target and prematurely destroy autologous red blood cells (RBCs), leading to hemolysis. AIHA is broadly classified into warm antibody AIHA (wAIHA, ~80–90% of cases), cold agglutinin disease (CAD, ~10–20%), and the rare mixed or atypical forms. The underlying pathophysiology involves loss of immunologic tolerance to RBC membrane antigens—most commonly Rh system antigens in wAIHA and I/i antigens in CAD—resulting in complement-mediated or Fc receptor–mediated phagocytosis and intravascular or extravascular hemolysis.

Common causes include primary (idiopathic) AIHA, which accounts for approximately 50% of wAIHA cases and lacks an identifiable underlying etiology, and secondary AIHA, which arises in association with systemic conditions. Lymphoproliferative disorders are the most frequent secondary cause: chronic lymphocytic leukemia (CLL) is associated with AIHA in 5–10% of patients; non-Hodgkin lymphoma, Hodgkin lymphoma, and Waldenström macroglobulinemia also confer elevated risk. Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, and inflammatory bowel disease are well-established triggers, particularly for wAIHA, due to generalized B-cell dysregulation and polyclonal autoantibody production. Infections—including Mycoplasma pneumoniae (strongly linked to acute CAD), Epstein-Barr virus (EBV), cytomegalovirus (CMV), HIV, hepatitis viruses, and malaria—can induce transient AIHA via molecular mimicry, epitope spreading, or polyclonal B-cell activation. Certain medications provoke immune-mediated hemolysis through hapten-dependent, immune complex–mediated, or autoantibody-induction mechanisms; notable examples include alpha-methyldopa (classic cause of warm IgG autoantibodies), fludarabine, rituximab (paradoxically, especially in CLL), penicillin, cephalosporins, and sulfonamides.

Risk factors encompass age, sex, and comorbid burden. wAIHA peaks in the sixth to eighth decades, with a female predominance (F:M ≈ 2–3:1); CAD shows bimodal incidence, with primary CAD typically occurring in older adults (>60 years) and secondary CAD more common in younger individuals with infectious triggers. A history of prior autoimmune disease, lymphoid malignancy, or splenectomy increases susceptibility. Splenectomy may unmask or exacerbate AIHA due to loss of central tolerance mechanisms and altered macrophage distribution.

Genetic factors contribute modestly but significantly. While AIHA is not inherited in a Mendelian pattern, polymorphisms in immune-regulatory genes influence susceptibility. Variants in FCGR2A (encoding FcγRIIa), FCGR3A, and HLA-DRB1*04 and *15 alleles have been associated with increased risk of wAIHA, likely affecting IgG binding affinity and antigen presentation. In CAD, clonal expansion of IGHV4-34–expressing B lymphocytes is nearly universal; somatic mutations in this immunoglobulin heavy-chain variable region gene confer intrinsic autoreactivity against the I antigen on RBCs. Germline variants in complement regulatory genes (e.g., CD55, CD59) are not causative but may modulate disease severity. Familial clustering is rare but reported, suggesting polygenic inheritance interacting with environmental exposures.

Environmental factors play a contributory role. Chronic antigenic stimulation—such as persistent viral infections (e.g., EBV latency), recurrent respiratory infections, or exposure to organic solvents—may promote B-cell hyperactivity and loss of self-tolerance. Geographic and seasonal patterns exist: CAD incidence rises during colder months, reflecting thermal amplitude effects on autoantibody binding kinetics and complement activation. Smoking has been weakly associated with increased AIHA risk, possibly via oxidative stress–induced RBC membrane alterations and enhanced immunogenicity. Occupational exposures to benzene or pesticides have not been definitively linked but remain under investigation given their hematotoxic and immunomodulatory potential. Importantly, AIHA is not caused by dietary deficiencies, toxins, or radiation exposure per se—but these may exacerbate hemolysis or impair compensatory erythropoiesis in susceptible individuals.

In summary, AIHA emerges from a complex interplay of immunogenetic predisposition, dysregulated adaptive immunity, and exogenous triggers. Accurate classification (warm vs. cold, primary vs. secondary) is essential for prognosis and therapy selection, as treatment strategies differ markedly—for instance, complement inhibitors (e.g., sutimlimab) are FDA-approved for CAD, whereas rituximab and corticosteroids remain first-line for wAIHA. Recognition of underlying causes and modifiable risk factors enables timely intervention and mitigates morbidity from chronic hemolysis, thromboembolism, and treatment-related complications.

Autoimmune Hemolytic Anemia (AIHA) is a heterogeneous group of disorders characterized by the immune-mediated destruction of autologous red blood cells (RBCs), leading to hemolysis and anemia. It is classified primarily into warm antibody AIHA (IgG-mediated, optimal at 37°C), cold agglutinin disease (CAD; IgM-mediated, optimal at 0–4°C), and mixed or rare variants (e.g., paroxysmal cold hemoglobinuria). Clinical presentation varies widely depending on the rate of hemolysis, underlying etiology (primary/idiopathic vs. secondary to lymphoproliferative disorders, autoimmune diseases, infections, or drugs), and patient comorbidities.

Early symptoms are often insidious and nonspecific, reflecting progressive anemia and low-grade hemolysis. Patients may report increasing fatigue, diminished exercise tolerance, mild shortness of breath on exertion, lightheadedness, or subtle pallor. Some experience intermittent, low-grade fever without infectious source—attributable to cytokine release during RBC phagocytosis. In warm AIHA, early signs may include mild jaundice (due to unconjugated hyperbilirubinemia) and dark urine (from increased urobilinogen excretion), though these are frequently overlooked. In CAD, early manifestations are often cold-induced: acrocyanosis, Raynaud-like phenomena, or painful, mottled discoloration of fingers, toes, ears, or nose upon cold exposure—sometimes preceding overt anemia by months. Drug-induced AIHA may present abruptly within days to weeks after initiation of offending agents (e.g., alpha-methyldopa, fludarabine, rituximab, cephalosporins, or piperacillin).

Typical symptoms reflect moderate-to-severe anemia and acute or chronic hemolysis. Marked fatigue, dyspnea at rest or with minimal activity, palpitations, and orthostatic dizziness are common. Pallor is evident on mucosal surfaces (conjunctivae, oral mucosa) and skin. Jaundice—typically scleral and generalized—is prominent due to elevated indirect bilirubin from heme catabolism. Dark, tea-colored or cola-colored urine results from hemoglobinuria in intravascular hemolysis (more frequent in CAD and PCH) or high-grade extravascular hemolysis overwhelming hepatic conjugation capacity. Splenomegaly occurs in ~30–40% of warm AIHA cases due to reticuloendothelial hyperactivity; it may be detected on physical exam as left upper quadrant fullness or dullness to percussion. Tachycardia and systolic flow murmurs may be present secondary to high-output cardiac state.

Accompanying symptoms depend on the underlying cause and systemic immune activation. In secondary AIHA, patients may exhibit features of associated conditions: lymphadenopathy, night sweats, and weight loss in chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma; arthralgias, rash, photosensitivity, or renal involvement in systemic lupus erythematosus (SLE); or recurrent sinopulmonary infections in common variable immunodeficiency (CVID). Cold-induced vasomotor symptoms—including numbness, paresthesias, and ulceration of distal extremities—are hallmark in CAD. Rarely, severe CAD may cause digital ischemia or gangrene. In drug-induced AIHA, rash, eosinophilia, or serum sickness-like features may co-occur. Patients with Evans syndrome (AIHA plus immune thrombocytopenia) may present with petechiae, purpura, or mucosal bleeding alongside anemic symptoms.

Complications arise from both chronic hemolysis and therapeutic interventions. Severe anemia can precipitate high-output heart failure, angina, or arrhythmias—particularly in elderly patients or those with preexisting cardiovascular disease. Chronic hemolysis leads to iron overload (even without transfusions) due to repeated RBC breakdown and ineffective erythropoiesis, potentially causing end-organ damage (e.g., hepatic fibrosis, cardiomyopathy, endocrine dysfunction). Pigment gallstones (bilirubin stones) develop in up to 30% of chronic AIHA patients, increasing risk for cholecystitis or choledocholithiasis. Thromboembolic events—including deep vein thrombosis, pulmonary embolism, and arterial stroke—are significantly elevated, especially in CAD and warm AIHA post-splenectomy, likely due to platelet activation, endothelial injury, and hypercoagulable states induced by complement activation and inflammatory cytokines. Hemolytic crises—triggered by infection, surgery, or pregnancy—can cause rapid hemoglobin decline, acute kidney injury (from hemoglobinuria-induced tubular toxicity), and metabolic acidosis. Immunosuppressive therapy increases risks of opportunistic infections (e.g., Pneumocystis jirovecii pneumonia), reactivation of latent viruses (e.g., HBV, VZV), and secondary malignancies.

Diagnosis relies on integrating clinical suspicion with laboratory and serologic evaluation. First-line testing includes complete blood count (CBC) revealing normocytic, normochromic anemia with reticulocytosis (often >5%), elevated lactate dehydrogenase (LDH), low haptoglobin, and unconjugated hyperbilirubinemia. Peripheral blood smear shows spherocytes (in warm AIHA), polychromasia, nucleated RBCs, and occasionally fragmented cells. The direct antiglobulin test (DAT or Coombs test) is central: positive in >95% of AIHA cases—warm AIHA typically DAT-positive for IgG ± C3d; CAD shows strong C3d positivity with negative IgG; mixed forms may be positive for both. Additional testing includes cold agglutinin titer (≥1:64 at 4°C supports CAD), Donath-Landsteiner test (positive in PCH), serum protein electrophoresis (to detect monoclonal gammopathy), flow cytometry for B-cell clonality (in suspected lymphoma), and HIV, hepatitis B/C, and EBV serologies when indicated. Bone marrow examination is not routinely required but may be performed to exclude hematologic malignancy or assess erythroid hyperplasia.

Differential diagnosis must exclude other causes of hemolytic anemia. Hereditary spherocytosis presents with similar spherocytes and jaundice but features negative DAT, family history, and osmotic fragility test positivity. G6PD deficiency causes episodic hemolysis triggered by oxidative stressors (drugs, fava beans, infection) and shows characteristic bite cells and Heinz bodies on supravital staining; DAT is negative. Microangiopathic hemolytic anemias (e.g., TTP, HUS, DIC) demonstrate schistocytes, thrombocytopenia, and organ dysfunction—DAT negative. Paroxysmal nocturnal hemoglobinuria (PNH) shows complement-mediated intravascular hemolysis, flow cytometry-confirmed GPI-anchored protein deficiency, and nocturnal hemoglobinuria—but DAT is typically negative. Drug-induced non-immune hemolysis (e.g., clostridial sepsis, snake envenomation) lacks DAT positivity and has distinct clinical contexts. Finally, alloimmune hemolysis (e.g., transfusion reactions, hemolytic disease of the fetus and newborn) is distinguished by history and identification of donor-specific antibodies rather than autoantibodies.

Autoimmune Hemolytic Anemia (AIHA) is a heterogeneous group of disorders characterized by premature destruction of red blood cells (RBCs) due to autoantibodies directed against erythrocyte antigens. Classified primarily as warm antibody AIHA (IgG-mediated, optimal at 37°C), cold agglutinin disease (IgM-mediated, optimal at 0–4°C), and mixed or atypical forms, AIHA requires prompt diagnosis and risk-stratified management. Treatment goals include halting hemolysis, correcting anemia, preventing complications (e.g., thromboembolism, renal injury, heart failure), and addressing underlying triggers—such as lymphoproliferative disorders, autoimmune diseases (e.g., SLE), infections (e.g., Mycoplasma pneumoniae, EBV), or drug exposure.

Conservative treatment serves as the cornerstone for mild-to-moderate cases and supportive care across all severities. Patients with hemoglobin >10 g/dL and stable clinical status may require only close observation, serial CBCs, reticulocyte counts, LDH, haptoglobin, and indirect bilirubin monitoring every 3–7 days initially. Avoidance of known precipitants is critical: patients with cold agglutinin disease must minimize cold exposure (e.g., wearing gloves, avoiding refrigerated environments); those with drug-induced AIHA discontinue the offending agent immediately. Transfusion support is indicated selectively—only when symptomatic anemia (e.g., dyspnea, angina, tachycardia, fatigue) or hemodynamic instability exists—and must be performed cautiously using warmed, leukoreduced RBC units. Crossmatching may be challenging due to pan-agglutination; phenotypically matched units (e.g., Rh- and Kell-negative) are preferred when feasible. Iron, folate, and vitamin B12 supplementation are recommended during active hemolysis to support compensatory erythropoiesis, particularly given increased RBC turnover.

First-line pharmacotherapy for warm AIHA is corticosteroids—typically oral prednisone 1.0–1.5 mg/kg/day (max 80 mg/day) for 1–3 weeks, followed by a slow taper over 3–6 months. Approximately 70–80% of patients respond within 2–3 weeks; however, relapse occurs in up to 50% upon discontinuation. For steroid-refractory, dependent, or relapsed cases, second-line agents include rituximab (375 mg/m² weekly × 4 doses), which achieves response rates of 60–80% and durable remission in ~40% at 2 years. Other immunosuppressants include mycophenolate mofetil (1000–1500 mg twice daily), azathioprine (2–3 mg/kg/day), cyclosporine (3–5 mg/kg/day), and newer agents such as fostamatinib (a SYK inhibitor approved in some jurisdictions for chronic immune thrombocytopenia, under investigation in AIHA). In cold agglutinin disease, rituximab monotherapy yields ~50% response; combination with bendamustine significantly improves depth and duration of response. Complement inhibitors—including sutimlimab (anti-C1s monoclonal antibody, FDA-approved for CAD) and ravulizumab (anti-C5)—are transformative for severe CAD, rapidly normalizing hemolysis markers and transfusion independence in >80% of treated patients. Intravenous immunoglobulin (IVIG) has limited utility in warm AIHA (short-lived effect, high cost) and is generally reserved for acute, life-threatening hemolysis pre-surgery or in pregnancy.

Surgical intervention is rarely indicated but remains pivotal in select scenarios. Splenectomy is considered third-line therapy for warm AIHA refractory to steroids and rituximab. The spleen is the primary site of IgG-opsonized RBC sequestration and destruction; removal confers durable remission in ~60% of responders, with median response duration exceeding 5 years. Preoperative vaccination (against Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis) and lifelong penicillin prophylaxis (especially in children and high-risk adults) are mandatory to mitigate overwhelming post-splenectomy infection (OPSI). Laparoscopic splenectomy is preferred for its reduced morbidity, shorter hospital stay (typically 2–3 days), and faster recovery. In rare cases of AIHA secondary to localized lymphoid malignancy (e.g., splenic marginal zone lymphoma), resection may be both diagnostic and therapeutic. Surgical management plays no role in primary cold agglutinin disease, as hemolysis occurs predominantly intravascularly via complement activation.

Treatment advantages in China reflect rapid integration of global evidence with robust domestic infrastructure. Major tertiary hospitals—such as Peking University People’s Hospital, Shanghai Ruijin Hospital, and West China Hospital—host specialized hematology centers with multidisciplinary AIHA task forces (hematologists, transfusion medicine specialists, clinical immunologists, and molecular pathologists). Access to rituximab and newer biologics is increasingly widespread through national health insurance reimbursement (e.g., rituximab covered since 2020 for refractory AIHA; sutimlimab undergoing Phase III trials in China). Domestic biosimilars (e.g., rituximab biosimilars approved by NMPA) reduce costs by >40% versus originators without compromising efficacy or safety. Advanced diagnostics—including flow cytometry for autoantibody characterization, next-generation sequencing for clonal lymphoid disorders, and complement functional assays—are routinely available in top-tier centers. Moreover, China’s large patient volume enables rapid enrollment in investigator-initiated trials (IITs) evaluating novel agents like efgartigimod (FcRn antagonist) and belumosudil (ROCK2 inhibitor), positioning Chinese centers at the forefront of AIHA therapeutics innovation.

Recovery advice emphasizes long-term vigilance and patient empowerment. Patients should monitor for signs of relapse (fatigue, pallor, jaundice, dark urine, palpitations) and seek immediate evaluation if hemoglobin drops >2 g/dL over 1 week or new symptoms emerge. Routine follow-up includes CBC and reticulocyte count every 1–3 months during remission, annual LDH/haptoglobin, and periodic screening for underlying lymphoproliferative disease (e.g., peripheral blood flow cytometry, CT imaging if clinically indicated). Lifestyle modifications include strict sun protection (for photosensitive patients on immunosuppressants), influenza/pneumococcal vaccination annually, avoidance of live vaccines during active immunosuppression, and cautious use of NSAIDs or anticoagulants due to bleeding/thrombosis risks. Psychosocial support is integral: AIHA’s chronic, relapsing nature contributes to anxiety and depression; referral to hematologic social workers or cognitive behavioral therapy programs is encouraged. Finally, patients should maintain a treatment diary documenting medications, side effects (e.g., hyperglycemia, insomnia, weight gain with steroids), transfusion history, and laboratory trends—facilitating shared decision-making and timely intervention. With contemporary, individualized management, most patients achieve sustained remission and near-normal life expectancy.